Our webmaster is not the greatest. As for the other thing, we do know the company intends ("plans") to pursue an AD prevention study, and that we have some pre-clinical research to support it. I suspect it's a bit premature to formally begin designs and planning, though not mentioning our intentions now in corp presentations does seem like an unfortunate omission.
As clinical support for 2-73 rolls in, we would eventually see it. Hopefully it doesn't wait until after the AD trial, but it might.